Patient selection for robotic radiosurgery for clinically localized prostate cancer: Come one, come all

Robotic Radiosurgery: Treating Prostate Cancer and Related Genitourinary Applications

Volumn , Issue , 2012, Pages 165-177

  Collins, Sean P ^a   Suy, Simeng ^a   Oermann, Eric ^a   Lie, Siyan ^a   Yu, Xia ^a   Hanscom, Heather ^a   Kim, Joy ^a   Sherer, Benjamin ^a   Park, Hyeon U ^a   Collins, Brian T ^a   McGeagh, Kevin ^a   Dawson, Nancy ^a   Lynch, John H ^b   Dritschilo, Anatoly ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b San Diego Composites Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; ONCOLOGY; PROTON BEAM THERAPY; ROBOTICS; UROLOGY;

HIGH-DOSE-RATE BRACHYTHERAPY; INTENSITY-MODULATED RADIATION THERAPY; LOCALIZED PROSTATE CANCER; LOW DOSE RATE BRACHYTHERAPY; MULTI-DISCIPLINARY TEAMS; RADIATION ONCOLOGISTS; RADICAL PROSTATECTOMY; SELECTION CRITERIA;

RADIOTHERAPY;

EID: 84891614600     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-11495-3_15     Document Type: Chapter

References (130)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
2. Caso JR, Mouraviev V, Tsivian M et al (2010) Prostate cancer: an evolving paradigm. J Endourol 24:805–809
3. Catalona WJ, Smith DS (1998) Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160:2428–2434
4. Pound CR, Partin AW, Epstein JI et al (1997) Prostatespecific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24:395–406
5. Zincke H, Oesterling JE, Blute ML et al (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850–1857
6. Swanson GP, Riggs MW, Earle JD et al (2002) Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol 42:212–216
7. Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984
8. Potosky AL, Davis WW, Hoffman RM et al (2004) Fiveyear outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96:1358–1367
9. Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261
10. Kuban DA, el-Mahdi AM, Schellhammer PF (1987) Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 30:420–426
11. Fuks Z, Leibel SA, Wallner KE et al (1991) The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21:537–547
12. Swanson GP, Riggs MW, Earle JD (2004) Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 59:406–411
13. Bagshaw MA, Cox RS, Ramback JE (1990) Radiation therapy for localized prostate cancer. Justification by longterm follow-up. Urol Clin North Am 17:787–802
14. Perez CA, Lee HK, Georgiou A et al (1993) Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 26:581–591
15. Shipley WU, Thames HD, Sandler HM et al (1999) Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA 281:1598–1604
16. del Regato JA, Trailins AH, Pittman DD (1993) Twenty years follow-up of patients with inoperable cancer of the prostate (stage C) treated by radiotherapy: report of a national cooperative study. Int J Radiat Oncol Biol Phys 26:197–201
17. Zagars GK, von Eschenbach AC, Johnson DE et al (1987) Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60:1489–1499
18. Collins S, McRae D, Gagnon G et al (2008) New directions in radiation therapy of prostate cancer: brachytherapy and intensity-modulated radiation therapy. In: Pestell R, Nevalainen M (eds) Prostate cancer signaling networks, genetics and New treatment strategies. Humana Press, Totowa
19. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74
20. Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233–1239
21. Peeters ST, Heemsbergen WD, Koper PC et al (2006) Doseresponse in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996
22. Huang EH, Pollack A, Levy L et al (2002) Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54:1314–1321
23. Boersma LJ, van den Brink M, Bruce AM et al (1998) Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41:83–92
24. Ling CC, Burman C, Chui CS et al (1996) Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 35:721–730
25. Zelefsky MJ, Fuks Z, Happersett L et al (2000) Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55:241–249
26. Zelefsky MJ, Fuks Z, Hunt M et al (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116
27. Cahlon O, Zelefsky MJ, Shippy A et al (2008) Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71:330–337
28. Crook JM, Raymond Y, Salhani D et al (1995) Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37:35–42
29. Dawson LA, Mah K, Franssen E et al (1998) Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys 42:1155–1161
30. Litzenberg DW, Balter JM, Hadley SW et al (2006) Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 65:548–553
31. Kupelian PA, Langen KM, Willoughby TR et al (2008) Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol 18:58–66
32. Loeffler JS, Smith AR, Suit HD (1997) The potential role of proton beams in radiation oncology. Semin Oncol 24: 686–695
33. Talcott JA, Rossi C, Shipley WU et al (2010) Patientreported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 303:1046–1053
34. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95–09. J Clin Oncol 28:1106–1111
35. Coen JJ, Zietman AL (2009) Proton radiation for localized prostate cancer. Nat Rev Urol 6:324–330
36. D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
37. Zelefsky MJ, Kuban DA, Levy LB et al (2007) Multiinstitutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327–333
38. Grimm PD, Blasko JC, Sylvester JE et al (2001) 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51:31–40
39. Kollmeier MA, Stock RG, Stone N (2003) Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57:645–653
40. Merrick GS, Butler WM, Wallner KE et al (2005) Monotherapeutic brachytherapy for clinically organconfined prostate cancer. W V Med J 101:168–171
41. Zelefsky MJ, Hollister T, Raben A et al (2000) Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261–1266
42. Brachman DG, Thomas T, Hilbe J et al (2000) Failure-free survival following brachytherapy alone or external beam irradiation alone for T1–2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 48:111–117
43. Potters L, Morgenstern C, Calugaru E et al (2005) 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173:1562–1566
44. Mitsuyama H, Wallner KE, Merrick GS (2006) Treatment of prostate cancer in obese patients. Oncology (Williston Park) 20:1191–1197, discussion 1198, 1206, 1208
45. Millender LE, Aubin M, Pouliot J et al (2004) Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59:6–10
46. Merrick GS, Butler WM, Wallner KE et al (2005) Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 65:95–100
47. Merrick GS, Butler WM, Wallner K et al (2002) Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 60:104–108
48. Stock RG, Stone NN, Tabert A et al (1998) A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101–108
49. Potters L, Cao Y, Calugaru E et al (2001) A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50:605–614
50. Wallner K, Merrick G, Sutlief S et al (2005) High-dose regions versus likelihood of cure after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62:170–174
51. Stone NN, Stock RG, Unger P (2005) Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol 173: 803–807
52. Urbanic JJ, Lee WR (2006) Update on brachytherapy in localized prostate cancer: the importance of dosimetry. Curr Opin Urol 16:157–161
53. Merrick GS, Butler WM, Tollenaar BG et al (2002) The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 52:461–468
54. Allen ZA, Merrick GS, Butler WM et al (2005) Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 62:981–987
55. Snyder KM, Stock RG, Hong SM et al (2001) Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50:335–341
56. Mueller A, Wallner K, Merrick G et al (2004) Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 59:1047–1052
57. Tran A, Wallner K, Merrick G et al (2005) Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63:150–154
58. Chen AB, D’Amico AV, Neville BA et al (2009) Provider case volume and outcomes following prostate brachytherapy. J Urol 181:113–118, discussion 118
59. Lee WR, de Guzman AF, Bare RL et al (2000) Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 46:83–88
60. Merrick GS, Butler WM, Lief JH et al (2000) Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47:121–128
61. Terk MD, Stock RG, Stone NN (1998) Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160:1379–1382
62. Bucci J, Morris WJ, Keyes M et al (2002) Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53:91–98
63. Bellon J, Wallner K, Ellis W et al (1999) Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 43:579–581
64. Kucway R, Vicini F, Huang R et al (2002) Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167:2443–2447
65. Stone NN, Marshall DT, Stone JJ et al (2010) Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? J Urol 183:634–639
66. Thomas MD, Cormack R, Tempany CM et al (2000) Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 47:905–908
67. Merrick GS, Butler WM, Galbreath RW et al (2001) Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology 57:524–529
68. Crook J, Toi A, McLean M et al (2002) The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. Brachytherapy 1:131–137
69. Hinerman-Mulroy A, Merrick GS, Butler WM et al (2004) Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59:1367–1382
70. Levine GN, D’Amico AV, Berger P et al (2010) Androgendeprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121: 833–840
71. Badiozamani KR, Wallner K, Sutlief S et al (1999) Anticipating prostatic volume changes due to prostate brachytherapy. Radiat Oncol Investig 7:360–364
72. McNeely LK, Stone NN, Presser J et al (2004) Influence of prostate volume on dosimetry results in real-time 125I seed implantation. Int J Radiat Oncol Biol Phys 58:292–299
73. Cesaretti JA, Stone NN, Stock RG (2004) Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Int J Radiat Oncol Biol Phys 60:648–653
74. Moran BJ, Stutz MA, Gurel MH (2004) Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 59:392–396
75. Patel AB, Waterman FM, Dicker AP (2003) A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy. Brachytherapy 2:223–228
76. Stock RG, Lo YC, Gaildon M et al (1999) Does prostate brachytherapy treat the seminal vesicles? a dose-volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 45:385–389
77. Ho AY, Burri RJ, Jennings GT et al (2007) Is seminal vesicle implantation with permanent sources possible? a dosevolume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy 6:38–43
78. Sylvester JE, Grimm PD, Blasko JC et al (2007) 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67:57–64
79. Dattoli M, Wallner K, True L et al (2007) Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology 69:334–337
80. Dattoli M, Wallner K, True L et al (2007) Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110:551–555
81. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095–1101
82. Fowler JF (2005) The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44:265–276
83. Haustermans KM, Hofland I, Van Poppel H et al (1997) Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37:1067–1070
84. Brenner DJ (2000) Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 48:315–316
85. Mate TP, Gottesman JE, Hatton J et al (1998) High doserate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 41:525–533
86. Martinez AA, Gustafson G, Gonzalez J et al (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53:316–327
87. Galalae RM, Kovacs G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90
88. Demanes DJ, Rodriguez RR, Altieri GA (2000) High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method. Radiother Oncol 57: 289–296
89. Syed AM, Puthawala A, Sharma A et al (2001) High-doserate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 8:511–521
90. Deger S, Boehmer D, Roigas J et al (2005) High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47:441–448
91. Hsu IC, Kyounghwa B, Shinohara K et al (2010) Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 78(3):751–758, Epub 2010 Mar 6
92. Martinez AA, Demanes J, Vargas C et al (2010) High-doserate prostate brachytherapy: an excellent acceleratedhypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33(5):481–488
93. Konishi K, Yoshioka Y, Isohashi F et al (2009) Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 75:1003–1007
94. Corner C, Rojas AM, Bryant L et al (2008) A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 72:441–446
95. Hoskin PJ, Bownes PJ, Ostler P et al (2003) High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 68:285–288
96. Simnor T, Li S, Lowe G et al (2009) Justification for interfraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol 93:253–258
97. Tiong A, Bydder S, Ebert M et al (2010) A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys 76:1066–1072
98. Krupski TL, Kwan L, Afifi AA et al (2005) Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 23:7881–7888
99. Livsey JE, Cowan RA, Wylie JP et al (2003) Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57:1254–1259
100. Higgins GS, McLaren DB, Kerr GR et al (2006) Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 65:982–989
101. Lukka H, Hayter C, Julian JA et al (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23:6132–6138
102. Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 68:1424–1430
103. Xie Y, Djajaputra D, King CR et al (2008) Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 72:236–246
104. Madsen BL, Hsi RA, Pham HT et al (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67:1099–1105
105. King CR, Brooks JD, Gill H et al (2009) Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73:1043–1048
106. Friedland JL, Freeman DE, Masterson-McGary ME et al (2009) Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 8:387–392
107. Katz AJ, Santoro M, Ashley R et al (2010) Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 10:1
108. Fuller DB, Naitoh J, Lee C et al (2008) Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70:1588–1597
109. Townsend NC, Huth BJ, Ding W et al (2011) Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 34(1):6–10
110. Kilby W, Dooley J, Kuduvalli G et al (2010) The CyberKnife robotic radiosurgery system in 2010. Technol Cancer Res Treat 9(5):433–452
111. Webb S (1999) Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac–testing IMRT to the limit? Phys Med Biol 44:1639–1654
112. Hossain S, Xia P, Huang K et al (2010) Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78(1):58–63
113. Merrick GS, Wallner KE, Butler WM (2003) Minimizing prostate brachytherapy-related morbidity. Urology 62: 786–792
114. Brandeis J, Pashos CL, Henning JM et al (2000) A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 89:1792–1799
115. Davis BJ, Pisansky TM, Wilson TM et al (1999) The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 85:2630–2637
116. Sohayda C, Kupelian PA, Levin HS et al (2000) Extent of extracapsular extension in localized prostate cancer. Urology 55:382–386
117. Teh BS, Bastasch MD, Mai WY et al (2003) Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J 9:454–460
118. Krauss D, Kestin L, Ye H et al (2011) Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 80(4):1064–1071
119. Roach M 3rd, Faillace-Akazawa P, Malfatti C et al (1996) Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35: 1011–1018
120. Kagawa K, Lee WR, Schultheiss TE et al (1997) Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 38:319–325
121. McLaughlin PW, Troyer S, Berri S et al (2005) Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys 63:479–491
122. Villeirs GM KLV, De Neve WJ et al (2005) Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 76:99–106
123. D’Amico AV (1996) The role of MR imaging in the selection of therapy for prostate cancer. Magn Reson Imaging Clin N Am 4:471–479
124. D’Amico AV, Schnall M, Whittington R et al (1998) Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 51:449–454
125. Clarke DH, Banks SJ, Wiederhorn AR et al (2002) The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants. Int J Radiat Oncol Biol Phys 52:903–910
126. Chao KK, Goldstein NS, Yan D et al (2006) Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys 65:999–1007
127. Kestin L, Goldstein N, Vicini F et al (2002) Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54:686–697
128. Roeske JC, Forman JD, Mesina CF et al (1995) Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 33:1321–1329
129. Liang J, Wu Q, Yan D (2009) The role of seminal vesicle motion in target margin assessment for online imageguided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 73:935–943
130. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106